Candidate system analysis in ADHD: Evaluation of nine genes involved in dopaminergic neurotransmission identifies association with DRD1

World Journal of Biological Psychiatry

Volumn 13, Issue 4, 2012, Pages 281-292

  Ribasés, Marta ^a,b   Ramos Quiroga, Josep Antoni ^a,c   Hervás, Amaia ^d   Sánchez Mora, Cristina ^a,b,e   Bosch, Rosa ^a,c   Bielsa, Anna ^a   Gastaminza, Xavier ^a   Lesch, Klaus Peter ^f   Reif, Andreas ^f   Renner, Tobias J ^f   Romanos, Marcel ^g   Warnke, Andreas ^f   Walitza, Susanne ^f,h   Freitag, Christine ⁱ   Meyer, Jobst ^j   Palmason, Haukur ^j   Casas, Miquel ^a,c   Bayés, Mònica ^k   Cormand, Bru ^e,l  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY OF TRIER   (Germany)

^k Centro Nacional de An Á Lisis Gen Ó Mico CNAG   (Spain)

^l CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

more..

Author keywords

Association study; Biological psychiatry; Childhood ADHD; DRD1; Genetics

Indexed keywords

BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DAT1 GENE; DBH GENE; DOPAMINERGIC NERVE CELL; DRD3 GENE; DRD4 GENE; DRD5 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; GERMANY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NEUROTRANSMISSION; RISK; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; TH GENE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; DOPAMINE BETA-HYDROXYLASE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; SPAIN;

EID: 84860435144     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.584905     Document Type: Article

References (67)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, et al. 1996. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93(5): 1945-1949. (Pubitemid 26079860)
2. Arnsten AF. 2006. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31(11): 2376-2383. (Pubitemid 44607054)
3. Arnsten AF, Dudley AG. 2005. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 1(1): 2.
4. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A, et al. 1995. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377(6548): 424-428.
5. Biederman J, Mick E, Faraone SV. 2000. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157(5): 816-818. (Pubitemid 30249663)
6. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, et al. 2005. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 134(1): 67-72. (Pubitemid 40411112)
7. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, et al. 2006. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11(10): 934-953. (Pubitemid 44470216)
8. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. 2004. Selecting a maximally informative set of singlenucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74(1): 106-120. (Pubitemid 38085242)
9. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP, et al. 1996. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53(7): 607-616. (Pubitemid 26240863)
10. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. 2003. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30(2): 306-311. (Pubitemid 36686852)
11. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL. 1998. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37(12): 1595-1602. (Pubitemid 28550433)
12. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. 1999. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354(9196): 2132-2133. (Pubitemid 30008900)
13. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbaumer K, Kung HF, et al. 2000. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27(10): 1518-1524.
14. Dudbridge F. 2003. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25(2): 115-121. (Pubitemid 37064867)
15. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. 1998. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fl uorine-18]fl uorodopa positron emission tomographic study. J Neurosci 18(15): 5901-5907. (Pubitemid 28341366)
16. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. 1999. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 156(8): 1209-1215. (Pubitemid 29374881)
17. Fallin D, Schork NJ. 2000. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 67(4): 947-959.
18. Fan X, Xu M, Hess EJ. 2010. D2 dopamine receptor subtypemediated hyperactivity and amphetamine responses in a model of ADHD. Neurobiol Dis 37(1): 228-236.
19. Faraone SV, Biederman J. 1998. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 44(10): 951-958. (Pubitemid 28545223)
20. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, et al. 2000. Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 48(1): 9-20. (Pubitemid 30407145)
21. Faraone SV, Biederman J, Mick E. 2006. The age-dependent decline of attention deficit hyperactivity disorder: a metaanalysis of follow-up studies. Psychol Med 36(2): 159-165. (Pubitemid 43126140)
22. Feng J, Sobell JL, Heston LL, Cook EH Jr, Goldman D, Sommer SS. 1998. Scanning of the dopamine D1 and D5 receptor genes by REF in neuropsychiatric patients reveals a novel missense change at a highly conserved amino acid. Am J Med Genet 81(2): 172-178. (Pubitemid 28259099)
23. Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, Boreatti-Hummer A, et al. 2010. Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD. Neuropsychopharmacology 35(3): 656-664.
24. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379(6566): 606-612. (Pubitemid 26052818)
25. Gizer IR, Ficks C, Waldman ID. 2009. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126(1): 51-90.
26. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, et al. 2007. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5): 644-645. (Pubitemid 46522604)
27. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. 1995. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 23(6): 729-749.
28. Holmes A, Hollon TR, Gleason TC, Liu Z, Dreiling J, Sibley DR, et al. 2001. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 115(5): 1129-1144. (Pubitemid 32906651)
29. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. 2005. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57(3): 229-238. (Pubitemid 40187366)
30. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. 2005. Patterns and predictors of attentiondeficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 57(11): 1442-1451. (Pubitemid 40798566)
31. Kim BN, Lee JS, Shin MS, Cho SC, Lee DS. 2002. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Statistical parametric mapping analysis. Eur Arch Psychiatry Clin Neurosci 252(5): 219-225.
32. Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. 2005. Internal and external validity of attentiondeficit hyperactivity disorder in a population-based sample of adults. Psychol Med 35(6): 817-827. (Pubitemid 40873382)
33. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. 2000. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285(2): 107-110. (Pubitemid 30227631)
34. Kuntsi J, Rijsdijk F, Ronald A, Asherson P, Plomin R. 2005. Genetic infl uences on the stability of attention-deficit/hyperactivity disorder symptoms from early to middle childhood. Biol Psychiatry 57(6): 647-654. (Pubitemid 40409703)
35. Lasky-Su J, Anney RJ, Neale BM, Franke B, Zhou K, Maller JB, et al. 2008. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B(8): 1355-1358.
36. Leo D, Sorrentino E, Volpicelli F, Eyman M, Greco D, Viggiano D, et al. 2003. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 27(7): 661-669. (Pubitemid 37414914)
37. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. 2007. No gene is an island: the fl ip-fl op phenomenon. Am J Hum Genet 80(3): 531-538.
38. Luca P, Laurin N, Misener VL, Wigg KG, Anderson B, Cate-Carter T, et al. 2007. Association of the dopamine receptor D1 gene, DRD1, with inattention symptoms in families selected for reading problems. Mol Psychiatry 12(8): 776-785. (Pubitemid 47172689)
39. Misener VL, Luca P, Azeke O, Crosbie J, Waldman I, Tannock R, et al. 2004. Linkage of the dopamine receptor D1 gene to attention-deficit/ hyperactivity disorder. Mol Psychiatry 9(5): 500-509. (Pubitemid 38903506)
40. Moll GH, Heinrich H, Trott G, Wirth S, Rothenberger A. 2000. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci Lett 284(1-2): 121-125. (Pubitemid 30193214)
41. Palmason H, Moser D, Sigmund J, Vogler C, Hanig S, Schneider A, et al. 2010. Attention-deficit/hyperactivity disorder phenotype is infl uenced by a functional catechol-O-methyltransferase variant. J Neural Transm 117(2): 259-267.
42. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. 2007. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6): 942-948. (Pubitemid 46972911)
43. Purcell S, Cherny SS, Sham PC. 2003. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19(1): 149-150. (Pubitemid 36150192)
44. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3): 559-575. (Pubitemid 47330214)
45. Ribases M, Hervas A, Ramos-Quiroga JA, Bosch R, Bielsa A, Gastaminza X, et al. 2008. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol Psychiatry 63(10): 935-945.
46. Ribases M, Bosch R, Hervas A, Ramos-Quiroga JA, Sanchez-Mora C, Bielsa A, et al. 2009. Case-control study of six genes asymmetrically expressed in the two cerebral hemispheres: association of BAIAP2 with attention-deficit/ hyperactivity disorder. Biol Psychiatry 66(10): 926-934.
47. Ribases M, Ramos-Quiroga JA, Hervas A, Bosch R, Bielsa A, Gastaminza X, et al. 2009b. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol Psychiatry 14(1): 71-85.
48. Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI. 2004. Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J Child Psychol Psychiatry 45(3): 577-588. (Pubitemid 38380134)
49. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH. 2002. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12(6): 497-499. (Pubitemid 34913533)
50. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A, et al. 1999. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry 156(6): 891-896. (Pubitemid 29260344)
51. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, et al. 1997. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 90(6): 991-1001. (Pubitemid 27408513)
52. Russell VA. 2002. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Behav Brain Res 130(1-2): 191-196. (Pubitemid 34195335)
53. Sagvolden T, Hendley ED, Knardahl S. 1992. Behavior of hypertensive and hyperactive rat strains: hyperactivity is not unitarily determined. Physiol Behav 52(1): 49-57.
54. Shaw P, Gornick M, Lerch J, Addington A, Seal J, Greenstein D, et al. 2007. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64(8): 921-931. (Pubitemid 47230616)
55. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, et al. 2005. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 57(11): 1293-1300. (Pubitemid 40798548)
56. Taylor AM, Bush A, Thomson A, Oades PJ, Marchant JL, Bruce-Morgan C, et al. 1997. Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. Arch Dis Child 76(4): 304-309. (Pubitemid 27174538)
57. Thapar A, O'Donovan M, Owen MJ. 2005. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 14(Spec No. 2): R275-282. (Pubitemid 41631896)
58. Thapar A, Langley K, Owen MJ, O'Donovan M C. 2007. Advances in genetic findings on attention deficit hyperactivity disorder. Psychol Med: 1-12.
59. Thompson M, Comings DE, Feder L, George SR, O'Dowd BF. 1998. Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. Am J Med Genet 81(3): 241-244. (Pubitemid 28211186)
60. Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, et al. 2005. The SNPlex genotyping system: a fl exible and scalable platform for SNP genotyping. J Biomol Tech 16(4): 398-406.
61. Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, et al. 1998. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci USA 95(24): 14494-14499. (Pubitemid 28549395)
62. Viggiano D, Vallone D, Welzl H, Sadile AG. 2002. The Naples High-and Low-Excitability rats: selective breeding, behavioral profile, morphometry, and molecular biology of the mesocortical dopamine system. Behav Genet 32(5): 315-333. (Pubitemid 35192993)
63. Volkow ND, Swanson JM. 2003. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160(11): 1909-1918. (Pubitemid 39619623)
64. Watanabe Y, Fujita M, Ito Y, Okada T, Kusuoka H, Nishimura T. 1997. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38(3): 470-474. (Pubitemid 27376906)
65. Weinshenker D, Miller NS, Blizinsky K, Laughlin ML, Palmiter RD. 2002. Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc Natl Acad Sci USA 99(21): 13873-13877. (Pubitemid 35215473)
66. Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, White FJ, et al. 1994a. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79(6): 945-955.
67. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, et al. 1994b. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79(4): 729-742. (Pubitemid 24363815)